Polymer Technology Division, Material and Chemical Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China.
Biomacromolecules. 2012 Jan 9;13(1):40-8. doi: 10.1021/bm2009558. Epub 2011 Dec 22.
The antibody bevacizumab (Avastin) has been used clinically to treat intraocular neovascular diseases based on its antivascular endothelial growth factor (VEGF) character. The anti-VEGF strategy for retinal neovascular diseases is limited by the short half-life of bevacizumab and thus requires frequent injections. This Article reports the sustained release of bevacizumab from a biocompatible material that is composed of a triblock copolymer of poly(2-ethyl-2-oxazoline)-b-poly(ε-caprolactone)-b-poly(2-ethyl-2-oxazoline) (PEOz-PCL-PEOz). The amphiphilic PEOz-PCL-PEOz triblock copolymer was synthesized in three steps. First, the PEOz was polymerized by methyl p-toluenesulfonate and 2-ethyl-2-oxazoline (EOz), and the living end was terminated by potassium hydroxide methanolic solution. Subsequently, the hydroxyl-PEOz was used as a macroinitiator for the ring-opening polymerization of ε-caprolactone using a Tin(II) octoate catalyst to synthesize the telechelic hydroxylated PEOz-PCL. Finally, the PEOz-PCL-PEOz triblock copolymer was obtained using the 1,6-hexamethylene diisocyanateas a coupling reagent. The PEOz-PCL-PEOz was chemically and molecularly characterized by GPC, (1)H NMR, and FTIR, and its aqueous solution (ECE hydrogel) showed a reversible sol (room temperature)-gel (physiological temperature) phase transition, which serves as an easy antibody-packing system with extended release. The biodegradability of ECE hydrogel was assessed by the porosity formation at different periods by scanning electron microscopy. The ECE hydrogel had no in vitro cytotoxicity on the human retinal pigment epithelial cell line by flow cytometry. The histomorphology and electrophysiology of the rabbit neuroretina were preserved after 2 months of intravitreal injection. In conclusion, the ECE hydrogel has a temperature-sensitive sol-gel phase transition and is effective in vitro. Its intraocular biocompatibility demonstrated its great potential to be widely used in biomedical applications for extended drug release.
抗体贝伐单抗(阿瓦斯汀)基于其抗血管内皮生长因子(VEGF)特性,已被临床用于治疗眼内新生血管疾病。抗 VEGF 策略治疗视网膜新生血管疾病受到贝伐单抗半衰期短的限制,因此需要频繁注射。本文报道了一种由聚(2-乙基-2-恶唑啉)-b-聚(ε-己内酯)-b-聚(2-乙基-2-恶唑啉)(PEOz-PCL-PEOz)三嵌段共聚物组成的生物相容性材料中贝伐单抗的持续释放。两亲性 PEOz-PCL-PEOz 三嵌段共聚物通过三步合成。首先,通过甲基对甲苯磺酸和 2-乙基-2-恶唑啉(EOz)聚合 PEOz,并用氢氧化钾甲醇溶液终止活性端。随后,用羟基-PEOz 作为辛酸亚锡催化剂开环聚合ε-己内酯的大分子引发剂,合成端羟基 PEOz-PCL。最后,用 1,6-己二异氰酸酯作为偶联试剂得到 PEOz-PCL-PEOz 三嵌段共聚物。通过 GPC、(1)H NMR 和 FTIR 对 PEOz-PCL-PEOz 进行了化学和分子表征,其水溶液(ECE 水凝胶)表现出可逆的溶胶(室温)-凝胶(生理温度)相转变,可作为一种易于包装抗体且具有延长释放效果的系统。通过扫描电子显微镜评估不同时间 ECE 水凝胶的多孔形成来评估其生物降解性。通过流式细胞术,ECE 水凝胶对人视网膜色素上皮细胞系无体外细胞毒性。兔神经视网膜的组织形态和电生理在玻璃体内注射 2 个月后得到保留。总之,ECE 水凝胶具有温度敏感的溶胶-凝胶相转变,在体外具有有效性。其眼内生物相容性表明,它具有作为广泛用于延长药物释放的生物医学应用的巨大潜力。